Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Returns
Return on assets-45%-3.9pp-41.1%-3.0pp-38.1%-3.7pp-34.4%+0.3pp-34.7%-4.5pp
Liquidity
Current ratio10.3×0.0×10.2×-0.2×10.4×+0.6×9.8×-1.8×11.6×-1.9×
Quick ratio10.3×0.0×10.2×-0.2×10.4×+0.6×9.8×-1.8×11.6×-1.9×
Cash ratio2.1×-0.2×2.3×-0.8×3.2×+0.6×2.6×-0.2×2.8×+0.1×
Leverage
Debt-to-assets0.0×0.0×0.0×0.0×0.0×
Valuation
Market capitalization$1.08B+151%$611.44M+74.5%$350.31M-24.3%$462.67M+4.5%$442.94M-37.5%
Enterprise value$1.01B+181%$525.79M+112%$248.16M-36.6%$391.37M+6.3%$368.13M-41.4%
Earnings yield-19.5%+20.0pp-36%+25.9pp-61.9%-17.2pp-44.7%-4.3pp-40.4%-16.8pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Cullinan Therapeutics, Inc.'s ratios come from?
Every ratio is computed from Cullinan Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.